
Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced new data from its LANTERN Phase 2 study of LYR-210 in adult patients with chronic rhinosinusitis (CRS) at the 2022 Combined Otolaryngology Spring Meetings (COSM) being held in Dallas, Texas.
LYR-210 is designed as an alternative to sinus surgery for the millions of CRS patients that remain symptomatic despite treatment.